Cepheid:医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Cepheid - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7442
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cepheid, a subsidiary of Danaher Corporation, is a molecular diagnostic company that develops, manufactures and markets molecular systems and tests for clinical and non-clinical markets. The company offers in vitro diagnostic tests for health care associated infections, critical infectious diseases, sexual health, and oncology and genetics; molecular diagnostic systems; and reagents and parts. Cepheid distributes its products directly and also through a network of distributors across Americas, Asia, Europe, Africa and the Middle East regions. The company has partnership with small and large biopharmaceutical companies to develop therapies in anti-infective, critical infectious disease and oncology areas. Cepheid is headquartered in Sunnyvale, California, the US.

Cepheid – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cepheid, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cepheid, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Cepheid, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cepheid, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Cepheid, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Cepheid, Medical Equipment, Deal Details 10
Partnerships 10
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics 10
SpeeDx Enters into Distribution Agreement with Cepheid 11
Novacyt Enters into Partnership with Cepheid 12
Cepheid, MedImmune and Combacte Enter into Agreement 13
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics 14
Sidney Kimmel Cancer Center Enters into Agreement with Cepheid 15
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers 16
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 17
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University 18
Debt Offering 19
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million 19
Acquisition 21
Danaher Acquires Cepheid 21
Cepheid – Key Competitors 23
Cepheid – Key Employees 24
Cepheid – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 27
Government and Public Interest 27
Feb 20, 2018: New IDSA/SHEA Guidelines Highlight Critical Role of PCR Testing in C. difficile Diagnosis 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Cepheid, Medical Equipment, Key Facts 2
Cepheid, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Cepheid, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cepheid, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Cepheid, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cepheid, Deals By Market, 2012 to YTD 2018 8
Cepheid, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics 10
SpeeDx Enters into Distribution Agreement with Cepheid 11
Novacyt Enters into Partnership with Cepheid 12
Cepheid, MedImmune and Combacte Enter into Agreement 13
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics 14
Sidney Kimmel Cancer Center Enters into Agreement with Cepheid 15
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers 16
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 17
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University 18
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million 19
Danaher Acquires Cepheid 21
Cepheid, Key Competitors 23
Cepheid, Key Employees 24
Cepheid, Subsidiaries 25

List of Figures
Cepheid, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Cepheid, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Cepheid, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Cepheid, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Cepheid, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cepheid, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Cepheid, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cepheid, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Cepheid:医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • JSR Corporation (4185):企業の財務・戦略的SWOT分析
    JSR Corporation (4185) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Avista Corp (AVA):企業の財務・戦略的SWOT分析
    Avista Corp (AVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Damco International B.V.
    Damco International B.V. - Strategy, SWOT and Corporate Finance Report Summary Damco International B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Studsvik AB (SVIK):企業の財務・戦略的SWOT分析
    Studsvik AB (SVIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Rose Petroleum plc (ROSE):石油・ガス:M&Aディール及び事業提携情報
    Summary Rose Petroleum plc (Rose Petroleum), formerly Vane Minerals plc is an oil and gas company. The company explores and produce oil and gas, silver, gold, copper, and uranium deposits across the US and Mexico. Its oil and gas project is located in Paradox Basin in Utah, the US, which covers over …
  • China Resources Power Holdings Co Ltd:発電所・企業SWOT分析
    China Resources Power Holdings Co Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informatio …
  • Lekoil Ltd (LEK):企業の財務・戦略的SWOT分析
    Summary Lekoil Ltd (Lekoil) is an oil and gas exploration and production company with interests in Nigeria and Namibia. The company owns oil and gas exploration and production properties such as Otakikpo marginal field, Nigeria Dahomey Basin OPL310 and Nigeria Dahomey Basin OPL 325 in Nigeria, and B …
  • Galena Biopharma Inc (GALE)-医療機器分野:企業M&A・提携分析
    Summary Galena Biopharma Inc (Galena) is a biopharmaceutical company that develops and markets therapies for the treatment of unmet medical needs and advance care. The company's pipeline products comprise NeuVax, NeuVax Present, NeuVax Hercepti, NeuVax Vadis, GALE-401 and GALE-301 folate binding pro …
  • Diamyd Medical AB (DMYD B):企業の財務・戦略的SWOT分析
    Summary Diamyd Medical AB (Diamyd), formerly Diamyd Therapeutics AB is a drug development company that offers diabetes vaccine. The company's diabetes products include Diamyd, an antigen-based immunotherapy for the treatment of autoimmune diabetes. Its pipeline products include GAD, GABA, and other …
  • Drugs for Neglected Diseases initiative:企業のM&A・事業提携・投資動向
    Drugs for Neglected Diseases initiative - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Drugs for Neglected Diseases initiative Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed re …
  • TS Corp (001790):企業の財務・戦略的SWOT分析
    TS Corp (001790) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • National Health Insurance Company – Daman PJSC:企業の戦略・SWOT・財務情報
    National Health Insurance Company - Daman PJSC - Strategy, SWOT and Corporate Finance Report Summary National Health Insurance Company - Daman PJSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Atos SE:企業の戦略・SWOT・財務情報
    Atos SE - Strategy, SWOT and Corporate Finance Report Summary Atos SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Casual Dining Group Ltd.:企業の戦略・SWOT・財務情報
    Casual Dining Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Casual Dining Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • The Boston Beer Company, Inc. (SAM):企業の財務・戦略的SWOT分析
    The Boston Beer Company, Inc. (SAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Twilio Inc (TWLO):企業の財務・戦略的SWOT分析
    Twilio Inc (TWLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Outokumpu Oyj:企業のM&A・事業提携・投資動向
    Outokumpu Oyj - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Outokumpu Oyj Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • HealthEquity Inc (HQY):企業の財務・戦略的SWOT分析
    Summary HealthEquity Inc (HealthEquity) is a healthcare service provider that offers health savings management services. The company provides integrated health accounts such as health savings account, health reimbursement arrangements, flexible spending accounts for health plans, insurance companies …
  • Endocyte Inc (ECYT):製薬・医療:M&Aディール及び事業提携情報
    Summary Endocyte Inc (Endocyte) is a biopharmaceutical company that develops targeted therapies for the treatment of cancer and inflammatory diseases. The company’s pipeline products include Lu-PSMA-617 and Ac-PSMA-617 for radiologand therapy, and FITC CAR-T. Endocyte's proprietary small molecule dr …
  • Mondi Plc (MNDI):企業の戦略的SWOT分析
    Mondi Plc (MNDI) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆